/PRNewswire/ UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to.
- UNI91103 has been selected as the first agent to be trialed in a study by UK investigators
- If successful, data generated will be used for registration of the product
- The study will include approx.1,500 kidney patients to assess if UNI91103 can prevent patients from contracting symptomatic COVID-19 and / or reduce serious illness and death from the infection
- Kidney patients are considered a high-risk patient population that may not respond well to vaccination
- Niclosamide has been demonstrated to prevent fatal outcomes in an animal model of COVID-19 when administered intranasally
1
HELLERUP, Denmark, Feb. 22, 2021 /PRNewswire/ UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to trial UNI91103 (intranasal niclosamide) as a prophylactic treatment of COVID-19 in kidney patients, a vulnerable and high-risk patient population.
UNI91103, developed by UNION therapeutics A/S, selected as first agent for prophylactic COVID-19 PROTECT-V study in high-risk patients prnewswire.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.co.uk Daily Mail and Mail on Sunday newspapers.
LifeArc provides £5m funding for COVID-19 genomics study
16th February 2021
LifeArc, a medical research charity, has announced it will provide £5m in funding to support the GenOMICC COVID-19 study, which is aiming to understand the role of genetic risk factors in patient responses to COVID-19.
The study, led by the GenOMICC consortium in partnership with Genomics England, is utilising genomics to evaluate why some people are affected more severely by COVID-19.
The partnership between the consortium and Genomics England was formed to allow for the large-scale and rapid whole genome sequencing and analysis of NHS COVID-19 patients.
“At Genomics England, we are proud to be working with the NHS, the University of Edinburgh and other partners in the fight against COVID-19, to understand why people respond so differently to this terrible infection,” said Chris Wigley, chief executive officer at Genomics England.
LifeArc supports the GenOMICC COVID-19 Study
Medical research charity, LifeArc, announces today that it is providing £5 million funding to support the work of the GenOMICC COVID-19 Study, led by the GenOMICC consortium in partnership with Genomics England. The study, launched in May 2020, is using genomics to investigate why some people are affected more severely by COVID-19, and increase our understanding about the disease.
GenOMICC is a global collaboration of doctors and scientists working together to understand and treat serious illnesses, including emerging infections like SARS, MERS and now COVID-19. The partnership with Genomics England was formed to enable large scale and rapid whole genome sequencing and analysis for NHS COVID-19 patients, leveraging Genomics England s sequencing and analysis ecosystem available to researchers.